The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
The model's full reasoning — Q4 2023 call → NOWe need to determine if management conveys that the heavy phase of a major undertaking is done and the collecting phase has begun but is early in the numbers. Key points from transcript: - Kevin Sayer: "2023 was an incredible year... Total revenue grew by 24%... We added over 600,000 Dexcom users... ended with 2.3 million customers... opening of our Malaysia manufacturing facility around mid-year. Production at this site is ramping quickly... This facility will help support our growth and cost ambitions for years to come." - "we not only generated $1 billion in Q4 revenue, we also delivered $1 billion in adjusted EBITDA for the year and generated record levels of free cash flow, which is up nearly 70% compared to 2022." - "we launched G7 and Dexcom 1 into multiple new markets... The rollout of G7 in the US in February... G7 is the most accurate CGM ever launched... market's reception has been exceptional... payers wasted no time establishing coverage... we completed the largest expansion of coverage in our company's history. In mid-April, Medicare coverage went live for people with type 2 diabetes using basal insulin only... we have effectively doubled our reimbursed population in the US." - "we expanded our prescriber base by approximately 40%... more than 70% of our new scripts are being written by primary care physicians." - "we are excited to continue our investment in our U.S. salesforce this year." - "we are thrilled to be introducing our newest product, Stelo, later this summer. Stelo will be the first CGM designed specifically for people with type 2 diabetes who are not on insulin... launch as a cash paid product... We filed Stelo with the FDA in the fourth quarter of 2023, leaving us well on track for our highly anticipated launch this summer." - "we have built a platform technology that we can customize... Our redesigned software infrastructure is a key component... we are further advancing this leadership position. We will also continue innovating on our hardware technology with our current efforts focused on launching an extended wear sensor across all of our product offerings." - Jereme Sylvain: "we reported worldwide revenue of $1.035 billion... growth of 27%... U.S. revenue... growth of 27%... International revenue grew 27%... Our fourth quarter gross profit was $664 million or 64.2% of revenue compared to 66.7%...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ARCB | ArcBest Corporation | Q4 2016 | 2017-02-08 | C |
IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.